CASE REPORT article
Front. Allergy
Sec. Therapies and Therapeutic Targets
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1604440
This article is part of the Research TopicBradykinin and Histamine Mediated AngioedemaView all 8 articles
Subcutaneous pdC1INH in pregnancy and lactation: Expanding treatment options for hereditary angioedema in Portugal
Provisionally accepted
- 1Allergy and Clinical Immunology Department, Unidade Local de Saúde de São João, Porto, Portugal
- 2Immunoallergology Department, Unidade Local de Saúde do Algarve, Faro, Portugal
- 3Public Health and Forensic Sciences and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of subcutaneous and/or submucosal angioedema. Pregnancy and breastfeeding may be associated with an increased frequency of attacks. Plasma-derived C1 inhibitor (pdC1INH) is the recommended first-line treatment for long-term prophylaxis (LTP) in these special populations. The pdC1INH currently available in Portugal is one intravenous (IV) formulation not approved for LTP, as are the other IV and subcutaneous (SC) formulations. Both patients remained free of angioedema episodes and reported no systemic adverse events. The safety of SC pdC1INH was consistent with reports in the literature.Overall, these positive results support the future use of SC pdC1INH in a broader population of pregnant and lactating women in clinical practice.
Keywords: hereditary angioedema, Lactation, Long-term prophylaxis, Plasma-derived C1 inhibitor, Pregnancy
Received: 01 Apr 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 Luísa Pinhal, Santos and Dias de Castro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ana Luísa Pinhal, Allergy and Clinical Immunology Department, Unidade Local de Saúde de São João, Porto, Portugal
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.